Suven gets patent grants for 2 products in Mexico, Korea
Suven Life Sciences has received patent grants for their two products in Mexico and Korea.
By INDIATIMES NEWS NETWORK |
MUMBAI: Suven Life Sciences has received patent grants for their two products in Mexico and Korea. The new chemical entities will be used for the treatment of disorders associated with neurodegenerative diseases. These patents are valid till 2023.
These granted patents are exclusive intellectual property of Suven and are achieved through internal discovery research efforts. Products out of these inventories which are in pre-clinical development may be out-licensed at the stage of clinical phase-I or Phase II stage.
"We are very pleased by the issuance of these patents to Suven for our drug candidates that are being developed for CNS disorders which targets an $18 billion potential market opportunity globally," said Venkat Jasti CEO of Suven.
The granted claims of the patents include the class of selective 5-HT compounds discovered by Suven and are being developed as therapeutic agents and are useful in the treatment of cognitive impairment associated with neurodegenerative disorders like attention deficient hyperactivity, Alzheimer's Parkinson, Schizophrenia and Huntington's.
Suven Life Sciences is a bio-pharmaceutical company focused on discovering, developing and commercialising novel pharmaceutical products. The company has six internally-discovered therapeutic drug candidates currently, in pre-clinical stage of development targeting conditions such as ADHD, dementia, depression, Huntington's disease. Parkinson's disease and obesity are in addition to developmental candidates in Alzheimer's disease and Schizophrenia.
At 11:08 pm, Suven shares were up 1.66 per cent at Rs 33.60 on BSE.
These granted patents are exclusive intellectual property of Suven and are achieved through internal discovery research efforts. Products out of these inventories which are in pre-clinical development may be out-licensed at the stage of clinical phase-I or Phase II stage.
"We are very pleased by the issuance of these patents to Suven for our drug candidates that are being developed for CNS disorders which targets an $18 billion potential market opportunity globally," said Venkat Jasti CEO of Suven.
The granted claims of the patents include the class of selective 5-HT compounds discovered by Suven and are being developed as therapeutic agents and are useful in the treatment of cognitive impairment associated with neurodegenerative disorders like attention deficient hyperactivity, Alzheimer's Parkinson, Schizophrenia and Huntington's.
Suven Life Sciences is a bio-pharmaceutical company focused on discovering, developing and commercialising novel pharmaceutical products. The company has six internally-discovered therapeutic drug candidates currently, in pre-clinical stage of development targeting conditions such as ADHD, dementia, depression, Huntington's disease. Parkinson's disease and obesity are in addition to developmental candidates in Alzheimer's disease and Schizophrenia.
At 11:08 pm, Suven shares were up 1.66 per cent at Rs 33.60 on BSE.
Too busy to trade in stocks? Invest in Mutual Funds with ET Money!
Bookmark or read stories offline -
Download ET Markets APP
Download ET Markets APP
ADVERTISEMENT
